NASDAQ:UTHR - United Therapeutics Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $227.14
Forecasted Upside: 29.24 %
Number of Analysts: 7
Breakdown:
0 Sell Ratings
0 Hold Ratings
7 Buy Ratings
0 Strong Buy Ratings

^$175.75 As of 06/24/2021 01:00 AM ET

▲ +1.11 (0.64%)

1 month | 3 months | 12 months

Get New United Therapeutics Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for UTHR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for UTHR

^$227.14

▲ +29.24% Upside Potential

This price target is based on 7 analysts offering 12 month price targets for United Therapeutics in the last 3 months. The average price target is $227.14, with a high forecast of $275.00 and a low forecast of $196.00. The average price target represents a 29.24% upside from the last price of $175.75.

Current Consensus is Buy

The current consensus among 7 investment analysts is to buy stock in United Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations Description Skip Past Price Target Consensus Chart

0 strong buy ratings
7 buy ratings
1 hold ratings
2 sell ratings

Ratings as of

1/1/2020

0 strong buy ratings
8 buy ratings
1 hold ratings
1 sell ratings

Ratings as of

3/31/2020

0 strong buy ratings
8 buy ratings
0 hold ratings
1 sell ratings

Ratings as of

6/29/2020

0 strong buy ratings
7 buy ratings
0 hold ratings
1 sell ratings

Ratings as of

9/27/2020

0 strong buy ratings
7 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

12/26/2020

0 strong buy ratings
7 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/26/2021

0 strong buy ratings
7 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/25/2021

0 strong buy ratings
7 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

6/24/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/6/2021	HC Wainwright	Boost Price Target	Buy	$195.00 ➝ $248.00	High
4/8/2021	JPMorgan Chase & Co.	Boost Price Target	Positive ➝ Overweight	$185.00 ➝ $212.00	High
2/25/2021	Wedbush	Boost Price Target	Outperform	$255.00 ➝ $260.00	Low
2/22/2021	Credit Suisse Group	Boost Price Target	Outperform	$169.00 ➝ $196.00	Low
2/16/2021	Oppenheimer	Boost Price Target	Outperform	$200.00 ➝ $275.00	Low
2/1/2021	HC Wainwright	Upgrade	Neutral ➝ Buy	$125.00 ➝ $195.00	Low
1/20/2021	Oppenheimer	Boost Price Target	Outperform	$175.00 ➝ $200.00	Low
1/20/2021	Cowen	Boost Price Target	Outperform	$160.00 ➝ $200.00	Low
1/20/2021	LADENBURG THALM/SH SH	Boost Price Target	Positive ➝ Buy	$151.00 ➝ $199.00	Low
10/29/2020	Wedbush	Boost Price Target	Outperform	$247.00 ➝ $255.00	Low
10/29/2020	Oppenheimer	Boost Price Target	Outperform	$165.00 ➝ $175.00	Medium
9/14/2020	JPMorgan Chase & Co.	Initiated Coverage	Overweight		High
7/30/2020	Oppenheimer	Boost Price Target	Outperform	$155.00 ➝ $165.00	Low
7/29/2020	Wedbush	Reiterated Rating	Buy	$243.00 ➝ $244.00	Low
6/25/2020	Wedbush	Reiterated Rating	Buy	$243.00	High
6/25/2020	Credit Suisse Group	Boost Price Target	Outperform	$129.00 ➝ $145.00	Medium
6/25/2020	HC Wainwright	Boost Price Target	Neutral	$85.00 ➝ $125.00	Medium
6/24/2020	Oppenheimer	Initiated Coverage	Buy	$155.00	Medium
6/17/2020	Wedbush	Reiterated Rating	Buy	$243.00	High
6/12/2020	Cowen	Reiterated Rating	Buy	$145.00	Medium
4/30/2020	Wedbush	Reiterated Rating	Buy	$243.00	Low
4/30/2020	Credit Suisse Group	Reiterated Rating	Buy		Low
3/10/2020	Jefferies Financial Group	Upgrade	Hold ➝ Buy	$115.00 ➝ $123.00	High
3/4/2020	Wedbush	Reiterated Rating	Buy	$243.00	Low
2/27/2020	Cowen	Upgrade	Market Perform ➝ Outperform	$119.00 ➝ $145.00	High
2/24/2020	Wedbush	Reiterated Rating	Outperform ➝ Buy	$237.00 ➝ $243.00	High
2/13/2020	Credit Suisse Group	Boost Price Target	Outperform	$113.00 ➝ $121.00	Low
2/3/2020	Wedbush	Reiterated Rating	Buy	$237.00	Low
1/31/2020	JPMorgan Chase & Co.	Upgrade	Neutral ➝ Overweight	$116.00 ➝ $120.00	Low
1/27/2020	Wedbush	Reiterated Rating	Buy	$237.00	High
12/15/2019	Wedbush	Reiterated Rating	Buy	$237.00	Medium
12/10/2019	Credit Suisse Group	Reiterated Rating	Buy	$113.00	Low
12/3/2019	Bank of America	Initiated Coverage	Underperform	$80.00	High
11/1/2019	HC Wainwright	Reiterated Rating	Hold	$85.00	Low
9/13/2019	Cowen	Set Price Target	Hold	$118.00	Low
8/1/2019	Wedbush	Reiterated Rating	Buy	$273.00	Low
8/1/2019	LADENBURG THALM/SH SH	Upgrade	Neutral ➝ Buy	$103.00 ➝ $106.00	High
8/1/2019	Jefferies Financial Group	Upgrade	Underperform ➝ Hold	$90.00	High
7/1/2019	Credit Suisse Group	Upgrade	Neutral ➝ Outperform	$98.00 ➝ $101.00	High
5/17/2019	UBS Group	Upgrade	Sell ➝ Neutral	$115.00 ➝ $94.00	Medium
5/9/2019	Credit Suisse Group	Upgrade	Underperform ➝ Neutral	$98.00	Medium
5/8/2019	Wedbush	Set Price Target	Buy	$273.00	Medium
5/2/2019	Wedbush	Boost Price Target	Outperform ➝ Outperform	$269.00 ➝ $273.00	High
5/1/2019	Cowen	Reiterated Rating	Hold	$103.00	High
4/9/2019	Oppenheimer	Lower Price Target	Outperform	$160.00 ➝ $155.00	Low
4/8/2019	Wedbush	Set Price Target	Buy	$269.00	High
3/26/2019	Oppenheimer	Set Price Target	Buy	$160.00	Low
3/26/2019	Credit Suisse Group	Reiterated Rating	Underperform	$105.00 ➝ $98.00	Medium
3/19/2019	Oppenheimer	Reiterated Rating	Buy		Medium
3/1/2019	Barclays	Lower Price Target	Underweight ➝ Underweight	$100.00 ➝ $95.00	Low
2/28/2019	LADENBURG THALM/SH SH	Set Price Target	Hold	$124.00	Low
2/27/2019	Cowen	Reiterated Rating	Hold	$109.00	Low
11/20/2018	Oppenheimer	Set Price Target	Buy	$160.00	Low
11/19/2018	Credit Suisse Group	Boost Price Target	Underperform ➝ Sell	$103.00 ➝ $105.00	Medium
11/15/2018	Cowen	Set Price Target	Hold	$106.00	High
11/2/2018	JPMorgan Chase & Co.	Boost Price Target	Neutral ➝ Neutral	$118.00 ➝ $126.00	Low
11/1/2018	Credit Suisse Group	Lower Price Target	Underperform ➝ Underperform	$106.00 ➝ $103.00	Low
11/1/2018	HC Wainwright	Reiterated Rating	Hold	$95.00	High
10/31/2018	Cowen	Set Price Target	Hold	$106.00	High
10/12/2018	Standpoint Research	Upgrade	Hold ➝ Buy		Low
9/27/2018	Wedbush	Set Price Target	Buy	$253.00	High
9/4/2018	Wedbush	Set Price Target	Buy	$253.00	High
8/13/2018	HC Wainwright	Set Price Target	Hold	$95.00	Medium
8/8/2018	Wedbush	Set Price Target	Buy	$253.00	Low
8/8/2018	Credit Suisse Group	Downgrade	Neutral ➝ Underperform		Low
8/2/2018	Cowen	Reiterated Rating	Hold	$110.00	Medium
8/2/2018	Barclays	Reiterated Rating	Sell	$100.00	High
8/2/2018	HC Wainwright	Reiterated Rating	Hold	$95.00	High
8/2/2018	Wedbush	Boost Price Target	Outperform ➝ Outperform	$234.00 ➝ $253.00	High
7/10/2018	Credit Suisse Group	Boost Price Target	Neutral ➝ Neutral	$104.00 ➝ $107.00	Medium
5/3/2018	Barclays	Lower Price Target	Underweight ➝ Underweight	$105.00 ➝ $95.00	Medium
5/3/2018	Credit Suisse Group	Lower Price Target	Neutral ➝ Neutral	$108.00 ➝ $104.00	Medium
4/3/2018	Credit Suisse Group	Upgrade	Underperform ➝ Neutral	$115.00	High
2/22/2018	Barclays	Reiterated Rating	Underweight ➝ Underweight	$115.00 ➝ $105.00	Low
2/22/2018	Credit Suisse Group	Reiterated Rating	Underperform ➝ Underperform	$120.00 ➝ $115.00	Medium
1/18/2018	Credit Suisse Group	Reiterated Rating	Underperform ➝ Underperform	$118.00	Low
1/5/2018	Oppenheimer	Boost Price Target	Outperform	$180.00	Low
12/27/2017	Wedbush	Reiterated Rating	Outperform ➝ Outperform	$213.00 ➝ $232.00	Medium
10/27/2017	Cowen	Reiterated Rating	Hold	$129.00	N/A
10/26/2017	HC Wainwright	Reiterated Rating	Hold	$95.00	N/A
9/8/2017	Oppenheimer	Reiterated Rating	Buy		Low
7/14/2017	Jefferies Financial Group	Reiterated Rating	Sell	$105.00	Low
7/6/2017	UBS Group	Reiterated Rating	Sell	$106.00	Low
6/8/2017	Jefferies Financial Group	Reiterated Rating	Sell	$105.00	Low
4/28/2017	Jefferies Financial Group	Reiterated Rating	Underperform	$116.00 ➝ $105.00	Low
4/27/2017	Wedbush	Reiterated Rating	Outperform ➝ Outperform	$229.00 ➝ $213.00	Low
4/26/2017	Cowen	Reiterated Rating	Hold	$121.00	Low
4/17/2017	HC Wainwright	Reiterated Rating	Hold	$95.00	Low
4/12/2017	Jefferies Financial Group	Reiterated Rating	Sell	$116.00	Low
4/11/2017	JPMorgan Chase & Co.	Set Price Target	Hold	$125.00	Low
4/4/2017	Wedbush	Reiterated Rating	Outperform	$229.00	Low
4/3/2017	Cowen	Downgrade	Outperform ➝ Market Perform	$140.00 ➝ $121.00	Low
4/3/2017	Oppenheimer	Reiterated Rating	Buy		Medium
4/3/2017	Credit Suisse Group	Reiterated Rating	Underperform	$120.00	High
3/29/2017	UBS Group	Initiated Coverage	Sell ➝ Sell	$112.00	N/A
3/17/2017	Jefferies Financial Group	Reiterated Rating	Underperform	$116.00	High
3/16/2017	Credit Suisse Group	Initiated Coverage	Underperform ➝ Underperform	$120.00	High
3/6/2017	Jefferies Financial Group	Downgrade	Hold ➝ Underperform	$149.47 ➝ $116.00	N/A
2/27/2017	Wedbush	Reiterated Rating	Outperform	$229.00	N/A
2/23/2017	LADENBURG THALM/SH SH	Downgrade	Buy ➝ Neutral	$145.00	N/A
2/23/2017	SVB Leerink	Boost Price Target	Market Perform	$127.00 ➝ $148.00	N/A
2/22/2017	Oppenheimer	Set Price Target	Buy	$160.00 ➝ $175.00	N/A
2/14/2017	Oppenheimer	Reiterated Rating	Buy		N/A
2/8/2017	Wedbush	Reiterated Rating	Outperform	$229.00	N/A
1/27/2017	Wedbush	Reiterated Rating	Outperform	$229.00	N/A
1/19/2017	Standpoint Research	Downgrade	Buy ➝ Hold		N/A
1/5/2017	Wedbush	Reiterated Rating	Outperform	$229.00	N/A
12/14/2016	Oppenheimer	Initiated Coverage	Outperform	$160.00	N/A
11/29/2016	Barclays	Downgrade	Equal Weight ➝ Underweight	$115.00 ➝ $100.00	N/A
11/4/2016	Wedbush	Reiterated Rating	Outperform	$229.00	N/A
10/28/2016	LADENBURG THALM/SH SH	Upgrade	Neutral ➝ Buy	$128.00 ➝ $138.00	N/A
10/27/2016	Cowen	Set Price Target	Buy	$144.00	N/A
9/23/2016	Cowen	Reiterated Rating	Buy	$144.00	N/A
8/23/2016	Argus	Reiterated Rating	Hold		N/A
7/29/2016	JPMorgan Chase & Co.	Lower Price Target	Neutral	$145.00 ➝ $129.00	N/A
7/29/2016	Jefferies Financial Group	Reiterated Rating	Hold	$120.00	N/A
7/29/2016	HC Wainwright	Reiterated Rating	Hold		N/A
7/28/2016	Wedbush	Reiterated Rating	Outperform	$229.00	N/A

(Data available from 6/24/2016 forward)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhance the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing OreniPro, RemoPro, Tyvaso DPI, Trevyent, Ralinepag, and Aurora-GT to treat PAH; Unexisome to treat bronchopulmonary dysplasia; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. It has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin; Caremark, L.L.C. to provide refills of implanted pumps at its infusion centers; DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of Remodulin; MannKind Corporation to develop and license treprostinil inhalation powder and Dreamboat devices; and Arena Pharmaceuticals, Inc. to develop ralinepag for the treatment of PAH. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Today's Range

Now: $175.75

$173.56

$176.69

50 Day Range

MA: $190.61

$170.47

$211.93

52 Week Range

Now: $175.75

$98.37

$212.62

Volume

402,477 shs

Average Volume

365,314 shs

Market Capitalization

$7.87 billion

P/E Ratio

19.42

Dividend Yield

N/A

Beta

0.51

Frequently Asked Questions

What sell-side analysts currently cover shares of United Therapeutics?

The following sell-side analysts have issued research reports on United Therapeutics in the last twelve months: Cowen Inc, Credit Suisse Group AG, HC Wainwright, JPMorgan Chase & Co., LADENBURG THALM/SH SH, Oppenheimer Holdings Inc., TheStreet, and Wedbush.
View the latest analyst ratings for UTHR.

What is the current price target for United Therapeutics?

7 Wall Street analysts have set twelve-month price targets for United Therapeutics in the last year. Their average twelve-month price target is $227.14, suggesting a possible upside of 29.2%. Oppenheimer Holdings Inc. has the highest price target set, predicting UTHR will reach $275.00 in the next twelve months. Credit Suisse Group AG has the lowest price target set, forecasting a price of $196.00 for United Therapeutics in the next year.
View the latest price targets for UTHR.

What is the current consensus analyst rating for United Therapeutics?

United Therapeutics currently has 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe UTHR will outperform the market and that investors should add to their positions of United Therapeutics.
View the latest ratings for UTHR.

What other companies compete with United Therapeutics?

Other companies that are similar to United Therapeutics include Amgen, Gilead Sciences, Regeneron Pharmaceuticals, Biogen, Vertex Pharmaceuticals, Alexion Pharmaceuticals, Seagen, Exact Sciences, Alnylam Pharmaceuticals, Incyte, BioMarin Pharmaceutical, Novavax, Repligen, Neurocrine Biosciences and Exelixis.

How do I contact United Therapeutics' investor relations team?

United Therapeutics' physical mailing address is 1040 SPRING ST, SILVER SPRING MD, 20910. The biotechnology company's listed phone number is 301-608-9292 and its investor relations email address is [email protected] The official website for United Therapeutics is www.unither.com.